OraSure Technologies, Inc. (NASDAQ: OSUR) announced on February 10, 2026 that Health Canada has granted a license for its OraQuick™ HIV Self‑Test, the first oral HIV self‑test approved in Canada. The approval allows the company to sell the test across the country, including in pharmacies, community testing sites and private homes, providing a rapid, 20‑minute result from an oral swab. This regulatory milestone expands OraSure’s footprint into a new geographic market and opens a significant revenue channel in a country with a growing demand for accessible HIV testing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.